Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women

In this study of 4758 HIV-1–serodiscordant heterosexual couples in Kenya and Uganda, daily antiretroviral prophylaxis (with tenofovir or emtricitabine–tenofovir) in the HIV-1–negative partner significantly decreased the risk of HIV infection. The use of antiretroviral medications for the prevention...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The New England journal of medicine Ročník 367; číslo 5; s. 399 - 410
Hlavní autoři: Baeten, Jared M, Donnell, Deborah, Ndase, Patrick, Mugo, Nelly R, Campbell, James D, Wangisi, Jonathan, Tappero, Jordan W, Bukusi, Elizabeth A, Cohen, Craig R, Katabira, Elly, Ronald, Allan, Tumwesigye, Elioda, Were, Edwin, Fife, Kenneth H, Kiarie, James, Farquhar, Carey, John-Stewart, Grace, Kakia, Aloysious, Odoyo, Josephine, Mucunguzi, Akasiima, Nakku-Joloba, Edith, Twesigye, Rogers, Ngure, Kenneth, Apaka, Cosmas, Tamooh, Harrison, Gabona, Fridah, Mujugira, Andrew, Panteleeff, Dana, Thomas, Katherine K, Kidoguchi, Lara, Krows, Meighan, Revall, Jennifer, Morrison, Susan, Haugen, Harald, Emmanuel-Ogier, Mira, Ondrejcek, Lisa, Coombs, Robert W, Frenkel, Lisa, Hendrix, Craig, Bumpus, Namandjé N, Bangsberg, David, Haberer, Jessica E, Stevens, Wendy S, Lingappa, Jairam R, Celum, Connie
Médium: Journal Article
Jazyk:angličtina
Vydáno: Waltham, MA Massachusetts Medical Society 02.08.2012
Témata:
Adenine - adverse effects
Adenine - analogs & derivatives
Adenine - therapeutic use
Adolescent
Adult
Anti-Retroviral Agents - adverse effects
Anti-Retroviral Agents - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiretroviral drugs
Antiretroviral therapy
Antiviral agents
Biological and medical sciences
CD4 antigen
Contraception Behavior - statistics & numerical data
Counseling
Deoxycytidine - adverse effects
Deoxycytidine - analogs & derivatives
Deoxycytidine - therapeutic use
Disease prevention
Double-Blind Method
Drug Combinations
Drug Resistance, Viral
Drug therapy
Emtricitabine
Female
General aspects
Heterosexuality
HIV
HIV Infections - epidemiology
HIV Infections - prevention & control
HIV Seropositivity
HIV-1 - genetics
HIV-1 - isolation & purification
Human immunodeficiency virus
Human viral diseases
Humans
Incidence
Infectious diseases
Male
Medical sciences
Middle Aged
Organophosphonates - adverse effects
Organophosphonates - therapeutic use
Pharmacology. Drug treatments
Pregnancy
Prophylaxis
RNA, Viral - blood
Sexual Behavior - statistics & numerical data
Tenofovir
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Young Adult
Human
Immunopathology
Antiretroviral agent
Heterosexuality
Sex
Male
AIDS
Immune deficiency
Infection
Medicine
Prevention
Viral disease
Antiviral
Female
Woman
ISSN:0028-4793, 1533-4406, 1533-4406
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:In this study of 4758 HIV-1–serodiscordant heterosexual couples in Kenya and Uganda, daily antiretroviral prophylaxis (with tenofovir or emtricitabine–tenofovir) in the HIV-1–negative partner significantly decreased the risk of HIV infection. The use of antiretroviral medications for the prevention of HIV type 1 (HIV-1) transmission is a promising strategy for reducing the spread of HIV-1. 1 – 4 Antiretroviral treatment for persons infected with HIV-1 provides important clinical benefits and substantially reduces infectiousness. 5 – 7 Antiretroviral prophylaxis is a potential HIV-1–prevention strategy for those not yet infected with HIV-1, administered either as postexposure prophylaxis after high-risk occupational or nonoccupational exposure or as preexposure prophylaxis in those with ongoing HIV-1 exposure. 8 , 9 The rationale for antiretroviral prophylaxis in persons with ongoing exposure is based on its efficacy in infants exposed to HIV-1 during birth and . . .
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1108524